Inspire Medical Systems (NYSE:INSP) Stock Gets Price Target Reduction from Barclays

Inspire Medical Systems (NYSE:INSP) had its target price lowered by Barclays from $65.00 to $62.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has an underweight rating on the stock.

A number of other equities analysts have also weighed in on INSP. Evercore set a $54.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. KeyCorp restated a “sector weight” rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Royal Bank Of Canada raised their target price on shares of Inspire Medical Systems from $60.00 to $75.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 1st. Oppenheimer raised shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a research note on Tuesday, August 4th. Finally, Wells Fargo & Company boosted their price target on Inspire Medical Systems from $56.00 to $69.00 and gave the company an “equal weight” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $71.24.

Inspire Medical Systems Stock Down 0.2%

NYSE:INSP opened at $66.45 on Tuesday. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The stock has a market cap of $1.93 billion, a PE ratio of 32.81, a price-to-earnings-growth ratio of 4.87 and a beta of 0.67. The firm’s fifty day simple moving average is $68.89 and its 200-day simple moving average is $58.38.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. Inspire Medical Systems had a return on equity of 7.32% and a net margin of 11.43%. The firm had revenue of $206.69 million during the quarter, compared to the consensus estimate of $204.31 million. During the same period last year, the business posted $0.38 EPS. Inspire Medical Systems’s quarterly revenue was down 7.9% on a year-over-year basis. Equities analysts anticipate that Inspire Medical Systems will post 1.29 earnings per share for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pinnacle Wealth Planning Services Inc. raised its position in shares of Inspire Medical Systems by 19.8% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock valued at $81,000 after purchasing an additional 194 shares in the last quarter. Apollon Wealth Management LLC boosted its stake in shares of Inspire Medical Systems by 5.6% during the 1st quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock valued at $206,000 after buying an additional 212 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Inspire Medical Systems by 25.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,526 shares of the company’s stock valued at $106,000 after buying an additional 305 shares during the last quarter. Yousif Capital Management LLC grew its position in shares of Inspire Medical Systems by 5.7% during the third quarter. Yousif Capital Management LLC now owns 7,552 shares of the company’s stock worth $524,000 after buying an additional 405 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Inspire Medical Systems by 68.5% during the third quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock worth $83,000 after buying an additional 488 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Piper Sandler and Robert W. Baird were reported as expecting the stock to appreciate, offering some support amid weaker sentiment. Piper Sandler forecast Baird forecast
• Positive Sentiment: A bullish analysis argued Inspire’s competitive advantage held up under a severe stress test, suggesting the company may retain durable long-term strengths. Bullish competitive-position analysis
• Neutral Sentiment: Q3 results were mixed: revenue of $206.7 million modestly exceeded estimates, while falling 7.9% year over year; reported EPS of $0.14 beat the $0.09 consensus but was below $0.38 a year earlier. This points to continued growth and profitability concerns despite the estimate beats. Q3 earnings call summary
• Negative Sentiment: Inspire narrowed its full-year 2026 earnings guidance, a signal investors may interpret as reduced visibility or a weaker outlook. 2026 guidance update
• Negative Sentiment: Barclays maintained its Sell rating, and coverage linked an analyst downgrade to a sharp decline in the shares. This adds pressure alongside questions about cash flow and whether the stock has fallen enough. Barclays rating Cash-flow valuation discussion

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.